TAGRISSO® (osimertinib) demonstrated 5.5-year median disease-free survival in the adjuvant treatment of patients with EGFR-mutated lung cancer

Press release content from Business Wire. The AP news staff was not involved in its creation.

Related Keywords

United States ,Japan ,Cambridge ,Cambridgeshire ,United Kingdom ,Paris ,France General ,France ,America ,Jessica Mcduell ,Masahiro Tsuboi ,Daiichi Sankyo ,Brendan Mcevoy ,Susan Galbraith ,National Cancer Center Hospital ,Astrazeneca ,Data Monitoring Committee ,Lung Ambition Alliance ,Department Of Thoracic Surgery Oncology ,European Society For Medical Oncology ,European Society ,Medical Oncology ,Thoracic Surgery ,National Cancer Center Hospital East ,Executive Vice President ,Prescribing Information ,South America ,Independent Data Monitoring Committee ,Rare Diseases ,Business Wire ,Health ,Europe ,Business ,Lifestyle ,Cancer ,Tumors ,Lung Cancer ,